Second, although we observe differential expression of key epigenetic modifiers between BRAF-mutant and BRAF-corrected CRC organoids and in BRAF-mutant versus BRAF-wildtype CRC tumors, these changes are modest in magnitude. This evidence concerns the gene BRAF and colorectal carcinoma.